A framework for personalized medicine: prediction of drug sensitivity in cancer by proteomic profiling.

ABSTRACT:

Background

The goal of personalized medicine is to provide patients optimal drug screening and treatment based on individual genomic or proteomic profiles. Reverse-Phase Protein Array (RPPA) technology offers proteomic information of cancer patients which may be directly related to drug sensitivity. For cancer patients with different drug sensitivity, the proteomic profiling reveals important pathophysiologic information which can be used to predict chemotherapy responses.

Results

The goal of this paper is to present a framework for personalized medicine using both RPPA and drug sensitivity (drug resistance or intolerance). In the proposed personalized medicine system, the prediction of drug sensitivity is obtained by a proposed augmented naive Bayesian classifier (ANBC) who

SUBMITTER: Kim DC 

PROVIDER: S-EPMC3380735 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature